These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 10478760)

  • 21. [Graves' disease].
    Willhauck MJ; Spitzweg C
    MMW Fortschr Med; 2008 Sep; 150(36-37):31-5. PubMed ID: 18988333
    [No Abstract]   [Full Text] [Related]  

  • 22. [Thyroid uptake and scintigraphy. Comparison of 123I and 99mTc with 131I].
    Suzuki M; Morikawa S; Miyamoto Y; Iijima S; Suo M
    Kaku Igaku; 1978 Feb; 15(1):91-100. PubMed ID: 580626
    [No Abstract]   [Full Text] [Related]  

  • 23. Subacute thyroiditis with highly positive thyrotropin receptor antibodies and high thyroidal radioactive iodine uptake.
    Fujii S; Miwa U; Seta T; Ohoka T; Mizukami Y
    Intern Med; 2003 Aug; 42(8):704-9. PubMed ID: 12924496
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Marine-Lenhart syndrome. Graves' disease with poorly functioning nodules.
    Chandramouly B; Mann D; Cunningham RP; Giegerich E
    Clin Nucl Med; 1992 Nov; 17(11):905-6. PubMed ID: 1424386
    [No Abstract]   [Full Text] [Related]  

  • 25. Therapy dose calculation in Graves' disease using early I-123 uptake measurements.
    Vemulakonda US; Atkins FB; Ziessman HA
    Clin Nucl Med; 1996 Feb; 21(2):102-5. PubMed ID: 8697676
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thyroid uptake of gallium in Graves' disease.
    Allard JC; Lee VW; Franklin P
    Clin Nucl Med; 1988 Sep; 13(9):663-6. PubMed ID: 3180616
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The significance of FDG uptake in bilateral thyroid glands.
    Chen YK; Chen YL; Cheng RH; Yeh CL; Lee CC; Hsu CH
    Nucl Med Commun; 2007 Feb; 28(2):117-22. PubMed ID: 17198352
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Delayed tc-99m sestamibi washout in graves' disease.
    Balan KK; Baltrop AH; Wishart GC
    Clin Nucl Med; 2003 Mar; 28(3):239-40. PubMed ID: 12592140
    [No Abstract]   [Full Text] [Related]  

  • 29. Hyperthyroidism with or without pyramidal lobe Graves' disease or disseminated autonomously functioning thyroid tissue?
    Wahl R; Müh U; Kallee E
    Clin Nucl Med; 1997 Jul; 22(7):451-8. PubMed ID: 9227866
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Indium-111-pentetreotide in Graves' disease.
    Kahaly G; Görges R; Diaz M; Hommel G; Bockisch A
    J Nucl Med; 1998 Mar; 39(3):533-6. PubMed ID: 9529305
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Retreatment of Graves' disease with radioiodine 131I.
    Charkes ND
    J Nucl Med; 1999 Jan; 40(1):215-6. PubMed ID: 9935081
    [No Abstract]   [Full Text] [Related]  

  • 32. Metastatic parotid tumor: a rare presentation for papillary carcinoma of thyroid.
    Malhotra G; Nair N; Awasare S; Baghel NS
    Clin Nucl Med; 2007 Jun; 32(6):488-90. PubMed ID: 17515766
    [No Abstract]   [Full Text] [Related]  

  • 33. Normal uptake of F-18 FDG in the sublingual gland.
    Bogsrud TV; Karantanis D; Lowe VJ
    Clin Nucl Med; 2006 Jan; 31(1):50. PubMed ID: 16374130
    [No Abstract]   [Full Text] [Related]  

  • 34. [111In-DTPA-D-Phe1] octreotide scintigraphy in thyroidal and orbital Graves' disease: a parameter for disease activity?
    Postema PT; Krenning EP; Wijngaarde R; Kooy PP; Oei HY; van den Bosch WA; Reubi JC; Wiersinga WM; Hooijkaas H; van der Loos T
    J Clin Endocrinol Metab; 1994 Dec; 79(6):1845-51. PubMed ID: 7989493
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Graves disease mimicking solitary autonomous nodule at scintigraphy.
    Marui S; Augusto GA; Watanabe T
    Clin Nucl Med; 2012 Mar; 37(3):287-8. PubMed ID: 22310259
    [No Abstract]   [Full Text] [Related]  

  • 36. Personalization of radioiodine treatment for Graves' disease: a prospective, randomized study with a novel method for calculating the optimal 131I-iodide activity based on target reduction of thyroid mass.
    Orsini F; Traino AC; Grosso M; Guidoccio F; Boni G; Volterrani D; Mariani G
    Q J Nucl Med Mol Imaging; 2012 Dec; 56(6):496-502. PubMed ID: 23358401
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A patient with an autonomously functioning thyroid nodule with papillary adenocarcinoma associated with Graves' hyperthyroidism.
    Tsuboi M; Shigemasa C; Ueta Y; Yoshida A; Kobayashi K; Mori T; Mashiba H
    Clin Nucl Med; 1995 Nov; 20(11):985-8. PubMed ID: 8565381
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Response rate and factors affecting the outcome of a fixed dose of RAI-131 therapy in Graves' disease: a 10-year Egyptian experience.
    El-Kareem MA; Derwish WA; Moustafa HM
    Nucl Med Commun; 2014 Sep; 35(9):900-7. PubMed ID: 24926901
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metastatic papillary carcinoma of the thyroid in a patient previously treated for Graves' disease.
    Yunusa GH; Kotze T; Brink A
    Ann Afr Med; 2014; 13(2):91-4. PubMed ID: 24705115
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Octreotide scintigraphy in thyroidal and orbital Graves' disease.
    Wiersinga WM; Gerding MN; Prummel MF; Krenning EP
    Thyroid; 1998 May; 8(5):433-6. PubMed ID: 9623738
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.